Statistically significant lower risk is seen for hospitalization. One study shows statistically significant improvement.
Meta analysis using the most serious outcome reported shows 46% [-173‑89%] lower risk, without reaching statistical significance. Results are worse for peer-reviewed studies. Early treatment is more effective than late treatment. Currently all studies are RCTs.
Currently there is limited data, with only 885 patients and only 37 control events for the most serious outcome in trials to date. Studies to date are from only 2 different groups.
Ensovibep requires IV infusion, but may be less variant dependent than monoclonal antibodies.
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., Mar 2024, preprint, 1 author.